Rigel Pharmaceuticals (RIGL) EBT Margin (2010 - 2026)

Rigel Pharmaceuticals' EBT Margin history runs 16 years deep, the most recent figure standing at 19.82% for Q1 2026.

• On a quarterly basis, EBT Margin fell 176.0% year-over-year to 19.82% in Q1 2026; TTM through Mar 2026 was 40.69%, a 2192.0% increase from a year earlier, with the FY2025 full-year figure at 41.4%, up 3115.0% from the prior year.
• EBT Margin slipped to 19.82% in Q1 2026 per RIGL's latest filing, from 32.54% in the prior quarter.
• Across five years, EBT Margin topped out at 58.99% in Q2 2025 and bottomed at 164.0% in Q1 2022.
• The 5-year median for EBT Margin is 0.03% (2023), against an average of 11.69%.
• Biggest YoY gain for EBT Margin was 11396 bps in 2022; the steepest drop was 21494 bps in 2022.
• Year by year, EBT Margin stood at 2.73% in 2022, then slumped by 99 bps to 0.03% in 2023, then surged by 85895 bps to 26.43% in 2024, then rose by 23 bps to 32.54% in 2025, then slumped by 39 bps to 19.82% in 2026.
• Per Business Quant, the three latest RIGL EBT Margin figures stand at 19.82% (Q1 2026), 32.54% (Q4 2025), and 39.76% (Q3 2025).